.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,695,739

« Back to Dashboard

Details for Patent: 7,695,739

Title:In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
Inventor(s): Cooper; Eugene R. (Berwyn, PA), Bullock; John A. (King of Prussia, PA), Chippari; John R. (Phonenixville, PA), Schaefer; John L. (Gilbertsville, PA), Patel; Rakesh A. (Bensalem, PA), Jain; Rajeev (Farmingham, MA), Strasters; Joost (Exton, PA), Ryde; Niels P. (Malvern, PA), Ruddy; Stephen B. (Schwenksville, PA)
Assignee: Elan Pharma International Limited (Athlone, County Westmeath, IE)
Filing Date:Jan 08, 2007
Application Number:11/650,412
Claims:1. An in vitro method for evaluating a solid dosage form, comprising: (a) dispersing a dosage form in a biorelevant medium, wherein the dosage form comprises at least one poorly water-soluble active agent, and wherein prior to incorporation into the solid dosage form, the active agent has an effective average particle size of greater than 2 microns; (b) measuring the particle size of the dispersed poorly water-soluble active agent; and (c) determining if the level of dispersibility is sufficient for in vivo effectiveness of the dosage form, wherein the level of dispersibility is sufficient for in vivo effectiveness of the dosage form if the dosage form disperses such that the particle size of the dispersed active agent particles resembles the particle size of the active agent prior to incorporation into the solid dosage form.

2. The method of claim 1, wherein the dosage form is selected from the group consisting of solid dosage forms, liquid dosage forms, semi-liquid dosage forms, dry powders, multiparticulates, sprinkles, tablets, capsules, lyophilized formulations, sachets, lozenges, syrups, liquids for injection, and liquids for oral delivery.

3. The method of claim 1, wherein the dosage form is selected from the group consisting of dosage forms intended for oral, pulmonary, nasal, parenteral, rectal, local, and buccal delivery.

4. The method of claim 1, wherein prior to incorporation into the dosage form the active agent has an effective average particle size selected from the group consisting of greater than 5 microns, greater than 10 microns, greater than 15 microns, and greater than 20 microns.

5. The method of claim 1, wherein the biorelevant aqueous media is selected from the group consisting of electrolyte solutions of strong acids, strong bases, weak acids, weak bases, and salts thereof, and mixtures of strong acids, strong bases, weak acids, weak bases, and salts thereof.

6. The method of claim 5, wherein the electrolyte solution is selected from the group consisting of an HCl solution having a concentration from about 0.001 to about 0.1 M, an NaCl solution having a concentration from about 0.001 to about 0.2 M, and mixtures thereof.

7. The method of claim 5, wherein the electrolyte solution is selected from the group consisting of about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.2 M NaCl or less, about 0.001 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.

8. The method of claim 5, wherein the electrolyte solution is selected from the group consisting of 0.01 M HCl and 0.1 M NaCl.

9. The method of claim 1, wherein the at least one active agent is selected from the group consisting of COX-2 inhibitors, anticancer agents, NSAIDS, proteins, peptides, nutraceuticals, anti-obesity agents, corticosteroids, elastase inhibitors, analgesics, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, beta-adrenoceptor blocking agents, cardiac inotropic agents, contrast media, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, xanthines, and acne medication.

10. The method of claim 1, wherein prior to incorporation into the dosage form the active agent has an effective average particle size selected from the group consisting of about 5 microns, about 10 microns, about 15 microns, and about 20 microns.

11. An in vitro method for evaluating a solid dosage form, comprising: (a) dispersing a dosage form in a biorelevant medium, wherein the dosage form comprises at least one poorly water-soluble active agent, and wherein prior to incorporation into the solid dosage form, the active agent has an effective average particle size of about 2 microns; (b) measuring the particle size of the dispersed poorly water-soluble active agent; and (c) determining if the level of dispersibility is sufficient for in vivo effectiveness of the dosage form, wherein the level of dispersibility is sufficient for in vivo effectiveness of the dosage form if the dosage form disperses such that the particle size of the dispersed active agent particles resembles the particle size of the active agent prior to incorporation into the solid dosage form.

12. The method of claim 11, wherein the dosage form is selected from the group consisting of solid dosage forms, liquid dosage forms, semi-liquid dosage forms, dry powders, multiparticulates, sprinkles, tablets, capsules, lyophilized formulations, sachets, lozenges, syrups, liquids for injection, and liquids for oral delivery.

13. The method of claim 11, wherein the dosage form is selected from the group consisting of dosage forms intended for oral, pulmonary, nasal, parenteral, rectal, local, and buccal delivery.

14. The method of claim 11, wherein the biorelevant aqueous media is selected from the group consisting of electrolyte solutions of strong acids, strong bases, weak acids, weak bases, and salts thereof, and mixtures of strong acids, strong bases, weak acids, weak bases, and salts thereof.

15. The method of claim 14, wherein the electrolyte solution is selected from the group consisting of an HCl solution having a concentration from about 0.001 to about 0.1 M, an NaCl solution having a concentration from about 0.001 to about 0.2 M, and mixtures thereof.

16. The method of claim 14, wherein the electrolyte solution is selected from the group consisting of about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.2 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.

17. The method of claim 14, wherein the electrolyte solution is selected from the group consisting of 0.01 M HCl and 0.1 M NaCl.

18. The method of claim 11, wherein the at least one active agent is selected from the group consisting of COX-2 inhibitors, anticancer agents, NSAIDS, proteins, peptides, nutraceuticals, anti-obesity agents, corticosteroids, elastase inhibitors, analgesics, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, beta-adrenoceptor blocking agents, cardiac inotropic agents, contrast media, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, xanthines, and acne medication.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc